BiDil Side Effects

Generic Name: hydralazine / isosorbide dinitrate

Note: This page contains information about the side effects of hydralazine / isosorbide dinitrate. Some of the dosage forms included on this document may not apply to the brand name BiDil.

Not all side effects for BiDil may be reported. You should always consult a doctor or healthcare professional for medical advice. Side effects can be reported to the FDA here.

For the Consumer

Applies to hydralazine / isosorbide dinitrate: oral tablet

If you experience any of the following serious side effects, stop taking hydralazine and isosorbide dinitrate and seek emergency medical attention:

  • an allergic reaction (difficulty breathing; closing of your throat; swelling of your lips, tongue, or face; or hives);

  • blurred vision and dry mouth;

  • irregular heartbeat; or

  • blood in your urine or stools;

  • numbness, tingling, pain, or weakness of your arms or legs;

  • fainting.

Other, less serious side effects may be more likely to occur. If you experience any of the following side effects, continue to take isosorbide and talk to your doctor:

  • headache or dizziness;

  • flushing (redness of the face, neck and chest);

  • nausea or vomiting;

  • fast heartbeat;

  • swollen ankles; or

  • weakness.

Side effects other than those listed here may also occur. Talk to your doctor about any side effect that seems unusual or that is especially bothersome.

For Healthcare Professionals

Applies to hydralazine / isosorbide dinitrate: oral tablet

Nervous system

Nervous system side effects associated with the combination product have included headache (50%), dizziness (32%), asthenia (14%), and paresthesia (4%). Somnolence has been reported in less than 2% of patients.

Nervous system side effects associated with hydralazine as a single agent have included peripheral neuropathy, which appears to be dose-related and is more common in slow acetylators. The neuropathy usually first presents as paresthesias, numbness, and tingling in the extremities. It is probably the result of pyridoxine deficiency, perhaps because formation of a pyridoxal-hydralazine complex inactivates the coenzyme, and can, therefore, be treated by administration of pyridoxine. Headache or dizziness have been reported in approximately 5% of patients receiving hydralazine.[Ref]

A 61-year-old man with hypertension developed ataxia, numbness, and lower extremity weakness approximately six months after beginning hydralazine (up to 300 mg per day) and reserpine therapy. The neuropathy partially resolved after reduction of the hydralazine dosage to 60 mg daily. A complete evaluation revealed that this man was a slow acetylator of hydralazine.[Ref]

Cardiovascular

Cardiovascular side effects associated with the combination product have included chest pain (16%), hypotension (8%), ventricular tachycardia (4%), and palpitations (4%).

Cardiovascular side effects associated with hydralazine as a single agent are related to its vasodilatory properties. Reflex tachycardia is commonly observed. Palpitations, flushing, edema, or chest pain have been reported in less than 5% of patients. The use of hydralazine in patients with severe chronic heart failure has been associated with ischemia, including episodes of myocardial infarction. In patients with pulmonary hypertension (PH) and chronic obstructive pulmonary disease (COPD), hydralazine may increase pulmonary artery hypertension, especially during periods of hypoxia. The use of hydralazine in these patients may, on rare occasions, result in profound hypotension, tachycardia, and even death. Rare cases of bradycardia or cardiac tamponade (associated with hydralazine-induced lupus) have been reported. Hydralazine does not have a deleterious effect on the lipid profile, and, in fact, has been shown to decrease total and LDL cholesterol.

Cardiovascular side effects associated with isosorbide dinitrate as a single agent have included flushing, hypotension, diaphoresis, weakness, sinus bradycardia, and unusual case reports of AV heart block. Unusual cases of edema have also been reported.[Ref]

Gastrointestinal

Gastrointestinal side effects associated with the combination product have included nausea (10%) and vomiting (4%).

Gastrointestinal side effects associated with isosorbide dinitrate as a single agent include mild nausea and constipation.[Ref]

Hematologic

A 71-year-old man with hypertension developed anorexia, weight loss, petechiae, and a microcytic anemia during therapy with hydralazine and oxprenolol. Evaluation for iron deficiency, hemolysis, or marrow depression was negative. The patient was found to have fecal blood loss, anti-DNA antibodies, decreased complement levels, a normal upper GI series, and biopsy-proven vasculitis. The syndrome resolved within two weeks after discontinuation of hydralazine.[Ref]

Hematologic abnormalities have been associated with the hydralazine-induced lupus-like syndrome. Anemia may be caused by one of at least four hydralazine-associated problems; hemolysis, the formation of a circulating anticoagulant, thrombocytopenia, and vasculitis. Rare cases of leukopenia and agranulocytosis have been reported.

Hematologic side effects associated with isosorbide dinitrate as a single agent are rare and include methemoglobinemia and at least one case of isosorbide dinitrate-induced hemolytic anemia.[Ref]

Immunologic

The lupus syndrome may present as arthralgias (most common), myalgias, lethargy, malaise, a typical erythematous rash, weight loss, or dyspnea, but may be found incidentally in asymptomatic patients by urinalysis (proteinuria, hematuria), blood chemistry (elevated ESR, antinuclear antibody), or chest X-ray (interstitial lung disease, rare). Hypocomplementemia is an extremely rare finding in hydralazine-induced lupus.[Ref]

Immunologic side effects associated with hydralazine as a single agent have included the development of a lupus-like syndrome, which is more likely in patients who receive 400 mg or more of hydralazine per day, in female patients, or in patients who are slow acetylators. Of patients who receive less than 200 mg or 400 mg or more per day of hydralazine, 40% and 50%, respectively, develop a positive ANA titer, and up to 6% and 14%, respectively, develop a lupus-like syndrome.[Ref]

Renal

In one study, rapidly progressive glomerulonephritis (RPGN) is described in 4 of 444 patients, all of whom were men who were treated for 5 to 11 years with daily hydralazine doses of 100 to 250 mg. In three of the four cases, biopsy revealed a focal and segmental glomerular necrosis with crescents and positive immunofluorescence. The antinuclear antibody titer became positive in three. Renal function improved in all but one after the withdrawal of hydralazine and institution of corticosteroid therapy. A number of other cases of RPGN are reported. It appears to be far more common in patients who are slow acetylators.[Ref]

Renal side effects including rare cases of rapidly progressive and focal glomerulonephritis associated with the hydralazine-induced lupus syndrome have been reported and are often accompanied by anemia, a positive anti-DNA antibody titer, and a positive ANA titer.

Isosorbide dinitrate can cause a reduction of glomerular filtration rate and free water clearance associated with significant increases in plasma renin and aldosterone in patients with liver cirrhosis. The changes are most remarkable in patients with ascites.[Ref]

Metabolic

Metabolic side effects associated with the combination product have included hyperglycemia (4%) and hyperlipidemia (3%). Hypercholesterolemia has been reported in less than 2% of patients.[Ref]

Respiratory

A 48-year-old woman with hypertension developed dyspnea, hemoptysis, pleurisy, proteinuria, and hematuria one year after beginning hydralazine (150 mg per day), polythiazide, and atenolol therapy. Other associated findings included an elevated ESR, antinuclear factor, anti-DNA titer, a positive LE test, and radiographic findings of diffuse interstitial lung disease. Two weeks after stopping hydralazine, the signs and symptoms of lupus with pulmonary involvement disappeared.[Ref]

Respiratory side effects associated with the combination product have included bronchitis (8%), sinusitis (4%), and rhinitis (4%).

Respiratory side effects associated with hydralazine as a single agent have included nasal stuffiness (seen in approximately 3% of patients). A case of "hydralazine lung" associated with hydralazine-induced lupus has been reported.[Ref]

Hypersensitivity

Hypersensitivity reactions including allergic reaction have been reported rarely in patients receiving the combination product. Angioedema has been reported in less than 2% of patients.

Hypersensitivity reactions associated with hydralazine as a single agent are rare. Many of the rare cases of hepatitis are believed to be due to hypersensitivity. A case of retroperitoneal fibrosis and of occupational asthma are believed to be due to hypersensitivity.

Hypersensitivity reactions associated with isosorbide dinitrate as a single agent including rare cases of pruritus and drug rash have been reported.[Ref]

A 44-year-old woman with hypertension and acute sinusitis developed acute renal failure, edema, and a generalized maculopapular erythematous rash during therapy with ampicillin (for sinusitis), hydrochlorothiazide, and hydralazine. A complete evaluation revealed bilateral hydronephrosis and hydroureters secondary to ureteral obstruction due to retroperitoneal fibrosis. Renal function returned to baseline after oral prednisone therapy. It is unclear whether this problem was due to one or more of her medications.[Ref]

Ocular

Ocular side effects associated with the combination product have included amblyopia (3%).[Ref]

Musculoskeletal

Musculoskeletal side effects including arthralgia, myalgia, and tendon disorder have been reported in less than 2% of patients receiving the combination product.[Ref]

Dermatologic

A 65-year-old man with ischemic cardiomyopathy developed a pruritic, erythematous, generalized rash within two months after beginning hydralazine (200 mg per day) therapy. There were no clinical or laboratory signs of lupus. The rash persisted upon gradual withdrawal of the patient's other medications, but cleared only after discontinuation of hydralazine. Rechallenge resulted in a recurrent pruritic rash.[Ref]

Dermatologic side effects including alopecia and sweating have been reported in less than 2% of patients receiving the combination product.

Dermatologic manifestations of hydralazine-induced lupus-like syndrome include cutaneous vasculitis. A generalized, pruritic rash without evidence of lupus has been associated with hydralazine. Rare cases of Sweet's syndrome (neutrophilic dermatosis) have been associated with hydralazine.[Ref]

Genitourinary

At least two cases of male impotence associated with hydralazine are reported. The mechanism is unclear. There was no evidence of a neuropathy in either case.[Ref]

Genitourinary side effects rarely associated with hydralazine as a single agent have included impotence.[Ref]

Hepatic

A 59-year-old woman with hypertension and cholecystic gallbladder disease developed abdominal pain, nausea, vomiting, painful hepatomegaly, elevated serum transaminases, direct hyperbilirubinemia, and liver biopsy findings of subacute hepatitis (with bridging necrosis) within two days after hydralazine was added to her medical regimen. The signs and symptoms of hepatitis resolved after all medications were withheld, but returned upon rechallenge with hydralazine.[Ref]

Hepatic reactions associated with hydralazine as a single agent are rare. Less than ten cases of hepatitis have been reported, many of which were believed to be due to hypersensitivity. Histological findings include hepatocellular, cholestatic, mixed hepatocellular-cholestatic, and granulomatous patterns.[Ref]

References

1. Gustafsson LL, Johannisson J, Garle M "Extradural and parenteral pethidine as analgesia after total hip replacement: effects and kinetics: a controlled clinical study." Eur J Clin Pharmacol 29 (1986): 529-34

2. Bernat JL "Cluster headaches from isosorbide dinitrate." Ann Neurol 6 (1979): 554-5

3. Laufen H, Leitold M, Wildfeuer A "Comparative pharmacokinetics of isosorbide nitrates after repeated doses of sustained release isosorbide dinitrate." Arzneimittelforschung 38 (1988): 1336-41

4. "Product Information. BiDil (hydralazine-isosorbide dinitrate)." NitroMed Inc, Lexington, MA.

5. May K, Eghbal B, Ahmadinejad M, Ensslin HD, Weiss M "Evaluation of effectiveness and tolerability of isosorbide mononitrate during a three-year period in patients with angina pectoris." Cardiology 79 (1991): 46-50

6. Dangel ME, Weber PA, Leier CB "Transient myopia following isosorbide dinitrate." Ann Ophthalmol 15 (1983): 1156-8

7. Purvin VA, Dunn DW "Nitrate-induced transient ischemic attacks." South Med J 74 (1981): 1130-1

8. Kanto JH "Oral isosorbide-5-mononitrate: pharmacokinetics and clinical efficacy." Int J Clin Pharmacol Ther Toxicol 25 (1987): 129-35

9. Danahy DT, Aronow WS "Hemodynamics and antianginal effects of high dose oral isosorbide dinitrate after chronic use." Circulation 56 (1977): 205-12

10. Elkayam U, Amin J, Mehra A, Vasquez J, Weber L, Rahimtoola SH "A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the treatment ofchronic congestive heart failure." Circulation 82 (1990): 1954-61

11. Sporl-Radun S, Betzien G, Kaufmann B, Liede V, Abshagen U "Effects and pharmacokinetics of isosorbide dinitrate in normal man." Eur J Clin Pharmacol 18 (1980): 237-44

12. Koch-Weser J "Hydralazine." N Engl J Med 295 (1976): 320-3

13. Uberbacher HJ, Steinorth G, Glocke M, Abshagen U "An open, long-term, multi-centre study of the anti-anginal efficacy and safety of isosorbide 5-mononitrate at low doses in patients with coronary heart disease." Pharmatherapeutica 3 (1983): 331-41

14. Tsujimoto G, Horai Y, Ishizaki T, Itoh K "Hydralazine-induced peripheral neuropathy seen in a Japanese slow acetylator patient." Br J Clin Pharmacol 11 (1981): 622-5

15. Lins L-E, Berglund J, Eliasson K, Wernersson B "Efficacy and tolerability of hydralazine, in conventional and slow-release preparations, during long-term treatment of primary hypertension." Clin Ther 5 (1983): 251-9

16. Rosenthal R "Visual hallucinations and suicidal ideation attributed to isosorbide dinitrate." Psychosomatics 28 (1987): 555-6

17. Danielson M, Kjellberg J, Ohman P, Wernersson B "Evaluation of once daily hydralazine in inadequately controlled hypertension." Acta Med Scand 214 (1983): 373-80

18. Mueller RA, Meienberg O "Hemicrania with oculosympathetic paresis from isosorbide dinitrate ." N Engl J Med 308 (1983): 458-9

19. Heepe W, Gathmann-Lewik U "Antianginal efficacy and tolerability of 50 mg sustained-release isosorbide 5-mononitrate in an open twelve-month observation study." Cardiology 74 (1987): 34-9

20. Aylward PE, Tonkin AM "Cardiac tamponade in hydrallazine-induced systemic lupus erythematosus." Aust N Z J Med 12 (1982): 546

21. Muikku O, Hynynen M, Salmenpera M, Harjula A, Heinonen J "Pulmonary vascular effects of trinitroglycerin and isosorbide dinitrate after cardiopulmonary bypass." Br J Anaesth 71 (1993): 720-4

22. Arsura E, Lichstein E, Guadagnino V, Nicchi V, Sanders M, Hollander G, Greengart A "Methemoglobin levels produced by organic nitrates in patients with coronary artery disease." J Clin Pharmacol 24 (1984): 160-4

23. Ferratini M "Risk of rebound phenomenon during nitrate withdrawal." Int J Cardiol 45 (1994): 89-96

24. Rodger JC "Peripheral oedema in patients treated with isosorbide dinitrate." Br Med J (Clin Res Ed) 283 (1981): 1365-6

25. Matsuhashi H, Onodera S, Hasebe N, Maruyama J, Honda H, Yamashita H, Tobise K "Transient pulsus alternans induced by isosorbide dinitrate: echocardiographic and hemodynamic evidence of reduced venous return-- a case report." Angiology 42 (1991): 504-11

26. Viskin S, Heller K, Porat R, Belhassen B "Complete atrioventricular block due to sublingual isosorbide dinitrate." South Med J 84 (1991): 369-70

27. Hammond TG, Mosesson MW "Fatal small-bowel necrosis and pulmonary hypertension in sickle cell disease." Arch Intern Med 149 (1989): 447-8

28. Miller AJ, Abrams DL, Kaplan BM "Persistent reversal of severe systemic hypertension after prolonged toxic reaction to hydralazine." Cardiology 60 (1975): 251-6

29. Packer M, Greenberg B, Massie B, Dash H "Deleterious effects of hydralazine in patients with pulmonary hypertension." N Engl J Med 306 (1982): 1326-31

30. Wehner RJ, Romanauskas VS "An adverse reaction with hydralazine: a case study." AANA J June (1981): 274-5

31. Carey RM, Coleman M, Feder A "Pericardial tamponade: a major presenting manifestation of hydralazine-induced lupus syndrome." Am J Med 54 (1973): 84-7

32. Haraoka S, Saito D, Miyasaka M, Kawasaki T, Yoshioka N, Ikenaga T, Okazaki S "A patient with repeated syncopal attacks after using isosorbide dinitrate." Acta Med Okayama 32 (1978): 369-78

33. Antonelli D, Barzilay J "Complete atrioventricular block after sublingual isosorbide dinitrate." Int J Cardiol 10 (1986): 71-3

34. Packer M, Meller J, Medina N, et al "Provocation of myocardial ischemic events during initiation of vasodilator therapy for severe chronic heart failure." Am J Cardiol 48 (1981): 939-46

35. Kronzon I, Cohen M, Winer HE "Adverse effect of hydralazine in patients with primary pulmonary hypertension." JAMA 247 (1982): 3112-4

36. Tuxen DV, Powles AC, Mathur PN, et al "Detrimental effects of hydralazine in patients with chronic air-flow obstruction and pulmonary hypertension." Am Rev Respir Dis 129 (1984): 388-95

37. Keller CA, Shepard JW, Chun DS, et al "Effects of hydralazine on hemodynamics, ventilation, and gas exchange in patients with chronic obstructive pulmonary disease and pulmonary hypertension." Am Rev Respir Dis 129 (1984): 606-11

38. Lodeiro JG, Feinstein SJ, Lodeiro SB "Fetal premature atrial contractions associated with hydralazine." Am J Obstet Gynecol 160 (1989): 105-7

39. Williams LL, Lopez LM, Thorman AD, et al "Plasma lipid profiles and antihypertensive agents: effects of lisinopril, enalapril, nitrendipine, hydralazine, and hydrochlorothiazide." Drug Intell Clin Pharm 22 (1988): 546-50

40. Fibuch EE, Cecil WT, Reed WA "Methemoglobinemia associated with organic nitrate therapy." Anesth Analg 58 (1979): 521-3

41. Scardi S, Zingone B, Pandullo C "Myocardial infarction following sublingual administration of isosorbide dinitrate." Int J Cardiol 26 (1990): 378-9

42. Laslett LJ, DeMaria AN, Amsterdam EA, Mason DT "Hydralazine-induced tachycardia and sodium retention in heart failure: hemodynamic and symptomatic correlation by prazosin therapy." Arch Intern Med 138 (1978): 819-20

43. Young EJ, Fainstein V, Musher DM "Drug-induced fever: cases seen in the evaluation of unexplained fever in a general hospital population." Rev Infect Dis 4 (1982): 69-77

44. Aderka D, Garfinkel D, Bograd H, Friedman J, Pinkhas J "Isosorbide dinitrate-induced hemolysis in G6PD-deficient subjects ." Acta Haematol 69 (1983): 63-4

45. Brooks AP, Paulley JW "Cutaneous manifestations of hydrallazine toxicity." Br Med J 02/16/80 (1980): 482

46. Sinzinger H, Virgolini I, O'Grady J, Rauscha F, Fitscha P "Modification of platelet function by isosorbide dinitrate in patients with coronary artery disease." Thromb Res 65 (1992): 323-35

47. Macleod WN "Anaemia in the hydrallazine-induced lupus syndrome." Scott Med J 28 (1983): 181-2

48. Widerlov E, Karlman I, Storsater J "Hydralazine-induced neonatal thrombocytopenia." N Engl J Med 303 (1980): 1235

49. Freestone S, Ramsay LE "Transient monoclonal gammopathy in hydralazine-induced lupus erythematosus." Br Med J 285 (1982): 1536-7

50. Orenstein AA, Yakulis V, Eipe J, Costea N "Immune hemolysis due to hydralazine." Ann Intern Med 86 (1977): 450-1

51. Bernstein RM, Egerton-Vernon J, Webster J "Hydrallazine-induced cutaneous vasculitis." Br Med J 280 (1980): 156-7

52. Sturman SG, Kumararatne D, Beevers DG "Fatal hydralazine-induced systemic lupus erythematosus." Lancet 12/03/88 (1988): 1304

53. Sequeira W, Polisky RB, Alrenga DP "Neutrophilic dermatosis (Sweet's Syndrome)." Am J Med 81 (1986): 558-60

54. Darwaza A, Lamey P-J, Connell JM "Hydrallazine-induced Sjogren's syndrome." Int J Oral Maxillofac Surg 17 (1988): 92-3

55. Pirmohamed M "Hydralazine-induced lupus: yet another autoantibody! triplex-DNA stabilization by hydralazine and the presence of anti-(triplex DNA) antibodies in patients treated with hydralazine - comment." Hum Exp Toxicol 15 (1996): 361-2

56. Shapiro KS, Pinn VW, Harrington JT, Levey AS "Immune complex glomerulonephritis in hydralazine-induced SLE." Am J Kidney Dis 3 (1984): 270-4

57. Finlay AY, Statham B, Knight AG "Hydrallazine-induced necrotising vasculitis." Br Med J 282 (1981): 1703-4

58. Cush JJ, Goldings EA "Southwestern internal medicine conference: drug-induced lupus: clinical spectrum and pathogenesis." Am J Med Sci 290 (1985): 36-45

59. Ludmerer KM, Kissane JM "Clinopathologic conference: renal failure, dyspnea and anemia in a 57 year old woman." Am J Med 71 (1981): 876-86

60. Innes A, Rennie JA, Cato GR "Drug-induced lupus caused by very-low-dose hydralazine." Br J Rheumatol 25 (1986): 225-31

61. Timbrell JA, Facchini V, Harland SJ, Mansilla-Tinoco R "Hydralazine-induced lupus: is there a toxic metabolic pathway?" Eur J Clin Pharmacol 27 (1984): 555-9

62. Kincaid-Smith P, Whitworth JA "Hydralazine-associated glomerulonephritis." Lancet 2 (1983): 348

63. Peacock A, Weatherall D "Hydralazine-induced necrotising vasculitis." Br Med J 282 (1981): 1121-2

64. Hahn BH, Sharp GC, Irvin WS, et al "Immune responses to hydralazine and nuclear antigens in hydralazine-induced lupus erythematosus." Ann Intern Med 76 (1972): 365-74

65. Bjorck S, Svalander C, Westberg G "Hydralazine-associated glomerulonephritis." Acta Med Scand 218 (1985): 261-9

66. Weinstein J "Hypocomplementemia in hydralazine-associated systemic lupus erythematosus." Am J Med 65 (1978): 553-6

67. Naparstek Y, Kopolovic J, Tur-Kaspa R, Rubinger D "Focal glumerulonephritis in the course of hydralazine-induced lupus syndrome." Arthritis Rheum 27 (1984): 822-5

68. Bass BH "Hydralazine lung." Thorax 36 (1981): 695-6

69. Ramsey-Goldman R, Franz T, Solano FX, Medsger TA "Hydralazine induced lupus and sweet's syndrome: report and review of the literature." J Rheumatol 17 (1990): 682-4

70. Cameron HA, Ramsay LE "The lupus syndrome induced by hydralazine: a common complication with low dose treatment." Br Med J 289 (1984): 410-12

71. Lunde PK, Frislid K, Hansteen V "Disease and acetylation polymorphism." Clin Pharmacokinet 2 (1977): 182-97

72. Ihle BU, Whitworth JA, Dowling JP, Kincaid-Smith P "Hydralazine and lupus nephritis." Clin Nephrol 22 (1984): 230-8

73. Fleming MG, Bergfeld WF, Tomecki KJ, et al "Bullous systemic lupus erythematosus." Int J Dermatol 28 (1989): 321-6

74. Blumenkrantz N, Christiansen AH, Ullman S, Asboe-Hansen G "Hydralazine-induced lupoid syndrome." Acta Med Scand 195 (1974): 443-9

75. Perry HM "Late toxicity to hydralazine resembling systemic lupus erythematosus or rheumatoid arthritis." Am J Med 54 (1973): 58-72

76. Widgren B, Berglund G, Andersson OK "Side-effects in long-term treatment with hydralazine." Acta Med Scand 714 (1986): 193-6

77. Evers J, Bonn R, Boertz A, Cawello W, Dickmans HA, Weiss M "Pharmacokinetics of isosorbide dinitrate, isosorbide-2-nitrate and isosorbide-5-nitrate in renal insufficiency after repeated oral dosage." Klin Wochenschr 67 (1989): 342-8

78. Salmeron JM, Ruiz del Arbol L, Gines A, Garcia-Pagan JC, Gines P, Feu F, Claria J, Rivera F, Bosch J, Arroyo V, et al "Renal effects of acute isosorbide-5-mononitrate administration in cirrhosis." Hepatology 17 (1993): 800-6

79. Perrin B, Malo J-L, Cartier A, et al "Occupational asthma in a pharmaceutical worker exposed to hydralazine." Thorax 45 (1990): 980-1

80. Waters VV "Hydralazine, hydrochlorothiazide and ampicillin associated with retroperitoneal fibrosis: case report." J Urol 141 (1989): 936-7

81. Gilmour E, Chalmers RJG, Rowlands DJ "Drug-induced sweet's syndrome (acute febrile neutrophilic dermatosis) associated with hydralazine." Br J Dermatol 133 (1995): 490-1

82. Schapel GJ "Skin rash and hydralazine." Med J Aust 141 (1984): 765-6

83. Keidan H "Impotence during antihypertensive treatment." Can Med Assoc J 114 (1976): 874

84. Rice D, Burdick CO "Granulomatous hepatitis from hydralazine therapy." Arch Intern Med 143 (1983): 1077

85. Itoh S, Yamaba Y, Ichinoe A, Tsukada Y "Hydralazine-induced liver injury." Dig Dis Sci 25 (1980): 884-7

86. Stewart GW, Peart WS, Boylston AW "Obstructive jaundice, pancytopenia and hydralazine." Lancet 05/30/81 (1981): 1207

87. Bartoli E, Massarelli G, Solinas A, et al "Acute hepatitis with bridging necrosis due to hydralazine intake." Arch Intern Med 139 (1979): 698-9

88. Myers JL, Augur NA "Hydralazine-induced cholangitis." Gastroenterology 87 (1984): 1185-8

89. Jori GP, Peschle C "Hydralazine disease associated with transient granulomas in the liver." Gastroenterology 64 (1973): 1163-7

90. Forster HS "Hepatitis from hydralazine." N Engl J Med 303 (1980): 1362

91. Podevin P, Biour M "Drug-induced ''allergic hepatitis''." Clin Rev Allergy Immunol 13 (1995): 223-44

92. Barnett DB, Hudson SA, Golightly PW "Hydralazine-induced hepatitis." Br Med J 05/10/80 (1980): 1165-6

More about BiDil (hydralazine / isosorbide dinitrate)

Consumer resources

Professional resources

Related treatment guides

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.

Hide
(web2)